Skip to the main content.
Contact Us

At Fluxion, we’re passionate about delivering cell-based and cell-free solutions that facilitate the transformation of research discoveries into new ways to diagnose and treat patients. By characterizing molecular and cellular mechanisms of disease, Fluxion’s platforms help bridge the translational medicine gap, enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests.

2 min read


April 29, 2016

UT Health will utilize Fluxion’s IsoFlux System for development of novel liquid biopsy approaches to improve diagnosis and treatment of cancer from a routine blood draw

SOUTH SAN FRANCISCO, Calif. -- Fluxion Biosciences announced today that it is collaborating with the University of Texas Health Science Center (Houston) to develop novel liquid biopsy approaches to improve the ability to diagnose, monitor, and treat cancer patients. The laboratory of Dr. Robert Amato is utilizing Fluxion’s IsoFlux System ( to isolate, recover, and analyze rare circulating cancer cells (CTCs) at the molecular level.

Ongoing access to cancer tissue represents one of the most significant challenges in characterizing cancer, and CTCs can alleviate this limitation by providing frequent, minimally-invasive access to cancer tissue via a blood draw. The high efficiency and high purity of CTCs recovered with IsoFlux system allows for the use of highly multiplexed analyses such as next-generation sequencing (NGS) for cancer mutational profiling. This “liquid biopsy” approach allows screening for a broad range of cancer biomarkers that will help guide treatment decisions using an emerging class of precision cancer therapies.

The collaboration with Dr. Amato will initially focus on prostate, kidney, and bladder cancers. One of the world’s leading experts in the treatment of genitourinary cancer, Dr. Amato, full professor and Director of the Division of Oncology at UTHealth Medical School and the Chief of the Division of Oncology at the Memorial Hermann Cancer Center, stated “We have already shown the ability to detect cancer in its early stages, and to measure tumor heterogeneity through single-cell analysis. The use of intact, live cells also offers the ability to measure gene and protein expression, and directly enables the use of mouse models for pharmacodynamic testing. Cancer is a dynamic disease, and the ability to track changes in each patient via a blood sample can allow actionable changes to be detected much earlier. One aim of the collaboration is to identify markers that can help stratify patients requiring more aggressive treatment from those that don’t. This is currently a major challenge in the treatment of prostate cancer.”

About Fluxion Biosciences
Fluxion’s IsoFlux CTC Liquid Biopsy System is used in clinical research for early cancer detection and patient monitoring. The IsoFlux System utilizes a novel microfluidic capture technology to isolate and purify circulating tumor cells (CTCs) from a blood sample, enabling cost-effective early detection and ongoing monitoring of actionable mutations via NGS without the need for a traditional biopsy. For more information about Fluxion Biosciences, visit

About University of Texas Health Science Center at Houston
The University of Texas Health Science Center at Houston (UTHealth) is Houston’s Health University and Texas’ resource for health care education, innovation, scientific discovery and excellence in patient care. UTHealth is home to schools of biomedical informatics, biomedical sciences, dentistry, medicine, nursing and public health. For more information, visit

Contact Information
Jeff Jensen
Fluxion Biosciences
Tel: 650-241-4777